Akero Therapeutics Inc (NAS:AKRO)
$ 18.32 -0.59 (-3.12%) Market Cap: 1.27 Bil Enterprise Value: 399.37 Mil PE Ratio: 0 PB Ratio: 1.50 GF Score: 42/100

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 06:30PM GMT
Release Date Price: $44.37 (+0.64%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Akero Therapeutics, and presenting on behalf of the company is CEO, Andrew Cheng.

There will be a Q&A after the presentation. Just raise your hand, and we'll get you a microphone. And for those folks tuning in online, you can submit a question via the digital conference (inaudible). So with that, Andrew, thank you.

Andrew Cheng
Akero Therapeutics, Inc. - President, CEO & Director

Good morning, and thank you, Eric.

So it's my pleasure to be here at -- in person at the '23 JPMorgan Healthcare Conference. And so why don't we go ahead and get started. So this is our safe harbor statement, of course, given the font size, I won't be reading that nor do you want to hear that. So I think we can -- now that it's been on the screen, we can move to the next slide.

So when we look at our corporate highlights and we think about what's happened in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot